This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Inogen (INGN) saw growth in revenues within its Rental segment in Q2.
Inogen (INGN) Q2 Earnings Beat Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 250.00% and -10.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Inogen (INGN) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Inogen in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Inogen (INGN) stock, thanks to solid prospects.
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 36.36% and 6.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Inogen (INGN) Stock for Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
3 Stocks in Focus as Coronavirus Boosts Medical Oxygen Demand
by Manaswita Ghosh Dutta
Oxygen therapy has emerged as a necessity for COVID-19 patients.
Inogen (INGN) Up 9.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold On to Inogen (INGN) Stock for Now
by Zacks Equity Research
Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
Inogen (INGN) sees segmental softness in the fourth quarter.
Inogen (INGN) Q4 Earnings Miss Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -36.36% and 0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Inogen
by Zacks Equity Research
Inogen, Inc. (INGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
New Strong Sell Stocks for January 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Inogen (INGN) Announces Preliminary Q4 Results, Slashes View
by Zacks Equity Research
Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.
Inogen (INGN) Up 7.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
Inogen (INGN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 34.78% and 0.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Inogen (INGN) Down 5.9% Since Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered
by Zacks Equity Research
Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.
Inogen (INGN) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -10.00% and -5.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?